Myelodysplastic syndromes
|
|
- Jeffry Davidson
- 7 years ago
- Views:
Transcription
1 Myelodysplastic syndromes - - treatment. (Who, when, what drugs?) Jaroslav Cermak, Institute of Hematology & Blood Transfusion, Prague, Czech Republic. Myelodysplastic syndromes Heterogeneous group of clonal hematological disorders arising from pluripotent progenitor stem cell. Different prognosis in terms of : - overall survival - leukemic transformation 1
2 MDS - development Second and subsequent hits: Loss of gene function ( hypermethylation tumor suppressors ) Gain of gene function ( oncogenes ) Noxa /insult: onkoproteins radiation First hit: Gene mutation : cell cycle transcription MDS early stage Increased apoptosis Impaired differentiation MDS late stage Decreased apoptosis Impaired differentiation Increased proliferation AML Normal stem cell Progress Dysplastic haemopoiesis Peripheral cytopenias No expansion of blasts Dysplastic haemopoiesis Peripheral cytopenias Expansion of blasts AML = acute myeloid leukaemia. W.K.Hoffman / with permission / Who should be treated? Prognostic factors : - traditional -new 2
3 FAB classification MDS subtype Blast percentage Peripheral Bone marrow blasts (%) blasts (%) Additional features AML transformation (%) RA Refractory anaemia 1 < RARS RA with ringed sideroblasts 1 < 5 > 15% ringed sideroblasts in bone marrow RAEB RA with excess blasts < > 50 RAEB-T RAEB in transformation Optional Auer rods CMML Chronic myelomonocytic leukaemia < 5 20 Peripheral monocytosis (> 10 3 /µl) > 40 Bennett JM, et al. Br J Haematol. 1982;51: Prognostic factors / traditional FAB
4 International Prognostic Scoring System (IPSS) Score Medullary blasts (%) < Karyotype Good * Intermediate Poor Cytopenia 0/1 2/3 Low risk 0 points Intermediate 1risk points Intermediate 2risk points High risk 2.5 points * Good: normal, Y, del(5q), del(20q). Intermediate: other abnormalities not seen in good or poor. Poor: complex ( 3 abnormalities) or chromosome 7 anomalies. Greenberg P, et al. Blood. 1997;89: Prognostic factors / traditional IPSS
5 Prognostic factors / traditional WHO
6 WHO Classification-Based Prognostic Scoring System (WPSS) Score Prognostic Variable WHO RA, RARS, 5q RCMD, RCMD-RS RAEB-1 RAEB-2 category Karyotype Good Intermediate Poor Transfusion requirement No Regular Verylow risk ik 0 points Low risk 1 points Intermediate 2 points High risk 3 4 points Very high risk 5 6 points Good: normal, Y, del(5q), del(20q). Poor: complex ( 3 abnormalities) or chromosome 7 anomalies Intermediate: other abnormalities Malcovati L et al, JCO, 25(23), 2007: Prognostic factors / traditional WPSS
7 New prognostic factors Revised cytogenetics, molecular cytogenetics Revised IPSS MDS Flow cytometry Molecular biology New prognostic cytogenetic scoring system Very good n = 81 (2.9%) Good n = 1,809 (65.7%) Intermediate n = 529 (19.2%) Poor n = 148 (5.4%) Very poor n = 187 (6.8%) Single del(11q) Y Overall survival (months) Normal Single del(5q) del(12p) del(20q) Double incl. del(5q) Single del(7q) +8 i(17q) +19 any others indep. clones Double any other Single der(3q) 7 Double incl. 7/7q Complex 3 abnormalities Complex 60,8 48,5 25,0 15,0 5,7 > 3 abnormalities Schanz J, et al. J Clin Oncol. 2011;29:
8 Molecular cytogenetics No significant difference in overall survival and progression free survival in patients with karyotype abnormalities diagnosed either by : chromosomal banding or molecular cytogenetics Tiu R V et al. Blood 2011;117: SNP microarray based karyotyping in MDS 8
9 5/15/2012 SNP array analysis impact on outcome High density SNP arrays have facilitated the detection of cryptic chromosomal aberrations(75% of MDS and AML have abnormal cytogenetics by SNP array) and are of prognostic importance but need to be evaluated in large prospective studies Next generation sequencing in MDS Mutated gene No. of samples All samples p 439 ((100)) 1.86 (( )) TET2 90 (20.5) 1.88 ( ) ASXL1 63(14.4) 1.33 ( ) RUNX1 38 (8.7) 1.16 ( ) < TP53 33 (7.5) 0.65 ( ) < EZH2 28 (6.4) 0.79 ( ) < NRAS 16 (3.6) 1.03 ( ) JAK2 13 (3.0) 2.14 ( ) 0.96 ETV6 12 (2.7) 0.83 ( ) 0.04 CBL 10 (2.3) 1.52 ( ) 0.02 IDH2 9 (2 (2.1) 1) 1 58 ( ( ) ) NPM1 8 (1.8) 2.18 ( ) 0.43 IDH1 6 (1.4) 3.30 ( ) 0.52 KRAS 4 (0.9) 0.89 ( ) 0.54 GNAS 3 (0.7) PTPN11 3 (0.7) BRAF 2 (0.5) PTEN 1 (0.2) CDKN2A 1 (0.2) Median survival (95% CI) (year) p value 0.48 Hazard Ratios for Death in a Multivariable Model.* Mutational status TP53 mutation present vs. absent 2.48 ( ) <0.001 EZH2 mutation present vs. absent 2.13 ( ) <0.001 ETV6 mutation present vs. absent 2.04 ( ) 0.03 RUNX1 mutation present vs. absent 1.47 ( ) ASXL1 mutation present vs. absent 1.38 ( ) Somatic point mutations are common in myelodysplastic syndromes and are associated with specific clinical features. Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 are predictors of poor overall survival in patients with myelodysplastic syndromes, independently of established risk factors. Bejar R, et al. N Engl J Med 2011;364:
10 5/15/2012 Flow cytometry Aberrant flow cytometry patterns well correlate with morphology, subclassification of MDS and with prognostic systems, but prospective validation of the impact of immunophenotypic patterns is necessarry. Loosdrecht et al., Haematologica 2008 Revised IPSS ( IPSS-R ) 7012 patients with primary MDS from 11 countries Significant parameters for prognostic classification : Hb, WBC, PLT (depth of cytopenias) new prognostic cytogenetic system (5 subgroups) percentage of bone marrow blasts 5 different prognostic subgroups survival leukemic transformation P.Greenberg with permission 10
11 Conclusions : all traditional prognostic systems : a significant difference in overall survival and risk of leukemic transformation between : very low, low, intermediate 1 and intermediate 2, high, very high subgroups. new prognostic parameters : mayhave a significant prognostic impact (SNP arrays, next generations sequencing of gene mutations, FCM) but their impact needs to be validated. When should we treat? 11
12 Favourable prognosis : prolonged survival, low risk of leukemic transformation Very low Low Intermediate 1 CONSERVATIVE TREATMENT RISK TREATMENT Intermediate 2 High Very high INTENSIVE TREATMENT Adverse prognosis : short survival, high risk of leukemic transformation INTENSIVE TREATMENT v.s. SUPPORTIVE CARE in MDS IPSS risk group SCT (+/- chemotherapy) nonsct relapse TRM 3yDFS 3yDFS LW IM IM H Degg et al., 2002, Greenberg et al.,
13 How should we treat? NON INTENSIVE TREATMENT INTENSIVE TREATMENT Control and modification of behaviour of the clone Eradication of the clone RBC and PLT transfusions chelation growth factors immune supression hypomethylating agents chemotherapy stem cell transplantation 13
14 Non-intensive treatment : correction of cytopenia RBC and PLT transfusions 0 > % of MDS patients 2 TU of RBC only 14% of patients 0 TU of RBC Iron overload the most serious consequence of repeated RBC transfusions Chelation treatment Removalofexistingiron surplusfromthebody Prevention of iron overload in MDS patients Who should be treated with chelators? - no definitive consensus - patients with serum ferritin > μg/l - patients who received > TU of RBC - measurement of NMR of heart using T2* - probably the best estimation of organ iron stores Who should receive chelators as a prophylaxis? - patients with isolated erythroid dysplasia receiving > 2 TU of RBC/month - presence of comorbidities (coronary disease, rheumatic disease) significantly increases risk of iron overload 14
15 Deferasirox - first line treatment of iron overloaded MDS patients -effectively decreases toxic iron (LPI level) - less effective than deferiprone in removal of iron from myocardium - chelation may lead to improvement in blood cell counts,? improvement in survival Deferiprone - not routinely used in MDS patients (risk of granulocytopenia) - alternative treatment for patients not indicated for deferasirox (adverse effects, renal insufficiency) Non-intensive treatment : Erythropoietin (EPO) MDS Score: 0 Probability of erythroid response 74% High ih Serum EPO (U/L) Transfusion requirement Score < 500 U/L U/L 1 < 2 prbc per month 2 prbc per month 0 1 Score: 1 23% Intermediate Score: 2 7% Low EPO may be combined with G CSF for treating anemia and granulocytopenia Administration of EPO may be connected with prolonged overall survival. Hellström Lindberg E, et al. Br J Haematol. 1997;99: Jädersten M,et al. Blood 2005;106 :
16 Non-intensive treatment : Immune suppression Total of 88 patients with MDS Randomized dti trial 45 patients with ATG+CSA 43 patients with BSC (RBC; Epo) Response rates ATG+CSA: 13/45 (29%) BSC: 4/43 (9%) Overall survival at 2 years ATG+CSA: 49% BSC: 63% p = BSC = best standard of care; OS = overall survival. Proportion remaining alive 1.0 ATG+CSA BSC ecrossover Time from randomization (years) Indication for immunosuppressive treatment : requested criteria LW or IM 1 IPSS score, patients who are indicated for treatment but not eligible for SCT. recommended criteria hypoplastic MDS, HLA Dr 15, PNH like MDS Passweg JR, et al. J Clin Oncol. 2011;29: Non-intensive treatment : Lenalidomide PATHOGENESIS OF 5q syndrome Jädersten et al.,haematologica 2010; 85, Lenalidomide in del 5q : reversion of SPARC gene function, expression of mirna 145, mirna 156a. stimulation of Cdc25c, PPAcα (regulation of cell cycle) 16
17 Non-intensive treatment : Lenalidomide (MDS 003,004) RBC TI (%) Transfusion independence (MDS 004) * * weeks of treatment Transfusion independence : MDS 003 : 69 % isolated del 5q 67% del 5q + complex abberations 52% del 5q + 1 abberation MDS 004 : 56% LW + IM1 patients + lenalidomide 10 mg/day x 28 41% LW + IM1 patients + lenalidomide 5 mg/day x 28 6% placebo List A, et al. N Engl J Med 2006; 355: , Fenaux P, et al. Blood. 2011;118: Risk analysis of outcome in del(5q) MDS treated or not with lenalidomide ce on Cumulative inciden of AML progressio Untreated LEN-treated Number of patients at risk, n Time (years) LEN-treated Untreated 2-year cumulative incidence 7% 12% 5-year cumulative incidence 23% 20% Median time to AML progression not reached not reached Kuendgen A, et al. Blood. 2011;118:[abstract 119]. 17
18 DNA hypermethylation and MDS N NH 2 DNA NH 2 methyltransferase N CH 3 O N Cytosine O N Cytosine + methyl group DNA methylation is regulated by DNA methyltransferases (DNMTs) Methylation occurs at CpG dinucleotides in DNA Esteller M. N Engl J Med 2008;358: MDS DNMTs hypermethylate cytosine bases of DNA in gene promoters Repressed transcription of tumour suppressor genes Dysregulated proliferation/differentiation of haematological precursor cells HYPOMETHYLATING AGENTS Methyl transferase inhibitiors : azacytidine, deoxyazacytidine Histon deacytelase inhibitors : vorinostat, valproic acid 18
19 AZA 001 overall Survival: Azacitidine vs CCR Proportion Surviving months 26.2% Log Rank p= HR = 0.58 [95% CI: 0.43, 0.77] Deaths: AZA = 82, CCR = 113 Difference: 9.4 months 50.8% 24.4 months 0.2 CCR Time (months) from Randomization AZA Fenaux et al., Lancet Oncol. 2009;10, Experience from treatment with azacytidine AZA signifcantly prolongs survival in comparison with conventional treatment regimens. Median number cycles to the first response is 2, to the best response is 3-4, 90% of responding patients respond within 6 cycles of treatment. Patients with poor-risk cytogenetics including abnormalities of chromosome 7 showed good response to AZA (not confirmed in more recent studies) AZA is well tolerated even in patients of age 75 and older. A significant effect on survival may be present even in patients who did not achieve CR or PR. 19
20 Survival (%) Intensive treatment : Combination chemotherapy (anthracycline + cytosin arabinoside) Combination chemotherapy not followed by SCT : limited impact on prolonged survival 3 years overall survival < 15% Wattel E. et al., Br J Haematol, 1997;98: less efficient than hypomethylating agents (AZA 001 study : OS 25,1 monhts for AZA v.s. 15,7 months for combination chemotherapy). Stem cell transplantation in MDS Which patients should be transplanted immediately, when can be SCT delayed? Should the patients with advanced MDS receive chemotherapy prior to SCT? What is the role of reduced conditioning regimens in MDS? 20
21 Stem cell transplantation : timing of SCT in relation to IPSS Cutler CS, et al. Blood. 2004;104: Low Int 1 s of discounted ctancy Gain/loss life expec High Int 2 Years of delay LW and INT 1 risk patients may benefit from delaying transplantation Patients with early MDS with profound pancytopenia and poor risk karyotype are indicated for immediate SCT (IM 2 risk score) Stem cell transplantation : effect of pretreatment with chemotherapy <10% blasts > 10% blasts Reduction of bone marrow blasts prior SCT may prolong survival of MDS patients with advanced disease. Randomized trials comparing upfront SCT and SCT after combination chemotherapy are needed. Cermak et al., Blood 2010; 116: 1638 De Witte et al. Blood 2001; 98:
22 Stem cell transplantation : effect of reduced conditioning standard conditioning reduced conditioning 3 years OS (%) years DFS (%) Martino et al.,blood 2006;108, Reduced conditioning regimens : low transplantation related mortality, higher incidence of relapses But : > 40% of patients survive > 3 years in recent studies relapse incidence (%) incidence nonrelapse mortality (%) FAB subtype (type of SCT + conditioning) DFS 3 years (%) TRM (%) Relapse (%) RA allosct RAEB allo/stand RAEB-T allo/stand RAEB + RAEB-T allo/reduced d RAEB + RAEB-T auto Degg et. al. (2005), Sierra et al. (2002), Martino et al. (2005), Mufti et al. (2005). 22
23 Conclusions Percentage of bone marrow blasts and karyotype abnormities are still the most important prognostic factors in MDS patients and play the most important role in the treatmentt tdecision i (intensive i v.s. conservative approach) Stem cell transplantation still represents the only curative treatment in MDS New factors e.g. molecular genetics changes may affect prognosis and choice of the appropriate treatment New drugs targeting the molecular basis of the disease (e.g. hypomethylating agents) representpromising therapeutic modalities in MDS. 23
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
More informationMyelodysplasia. Dr John Barry
Myelodysplasia Dr John Barry Myelodysplasia Group of heterogenouus bone marrow disorders that are due to a defect in stem cells. Increasing bone marrow failure leading to quan>ta>ve and qualita>ve abnormali>es
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationRisk Stratification in AML. Michelle Geddes Feb 27, 2014
Risk Stratification in AML Michelle Geddes Feb 27, 2014 Objectives Outline the challenges in post-remission therapy for AML Review etiology of disease escape mechanisms from therapy Evaluate prognostic
More informationPoročilo EHA 2012. Simon Bitežnik
Poročilo EHA 212 Simon Bitežnik 1 Burden of chronic anaemia in patients with MDS Anaemia is a major clinical problem in patients with MDS ~8% patients are anaemic at diagnosis 1 In patients with MDS, anaemia
More informationPage 1. Current Concepts: Etiology, Clinical Manifestations, and Treatment. Gary Schiller, MD
Treating Higher-Risk Myelodysplasia Current Concepts: Etiology, Clinical Manifestations, and Treatment Gary Schiller, MD Presentations in Two Patients 86 y.o. male with a 6-y hx of macrocytic anemia referred
More informationBoolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia
Boolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia Subarna Sinha PhD Department of Computer Science Principal Investigator: David Dill Daniel
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationGuidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Nordic MDS Group
Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Nordic MDS Group Issue 7 6 th update, 1 st of February 2014 1 WRITING COMMITTEE... 4 CONTACT
More informationWhy discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
More informationRole of Stem Cell Transplantation in Patients With MDS. Anastasios Raptis MD, Ph.D.
Role of Stem Cell Transplantation in Patients With MDS Anastasios Raptis MD, Ph.D. Disclosures Millennium Celgene MDS: Biology Heterogeneous group of clonal acquired disorders Ineffective hematopoiesis
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationLEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova
LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired
More informationAcute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
More informationMyelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma Hodgkin Lymphoma Overview Case Pathophysiology Diagnosis
More informationUnderstanding Myelodysplastic Syndromes: A Patient Handbook
UNITED STATES Understanding Myelodysplastic Syndromes: A Patient Handbook Sixth Edition the myelodysplastic syndromes foundation, inc. Published by The Myelodysplastic Syndromes Foundation, Inc. Understanding
More informationTreatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
More informationDNA Methylation in MDS/MPD/AML: Implications for application
DNA Methylation in MDS/MPD/AML: Implications for application James G. Herman, M.D. Professor of Oncology Evelyn Grollman Glick Scholar The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Disclosures
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationMDetails about molecular abnormalities; the SEER incidence data; link to PNH; new WPSS score, additional
yelodysplastic Syndromes (MDS) Drs. Rena Buckstein & Richard Wells Updated May 2008* Updates: MDetails about molecular abnormalities; the SEER incidence data; link to PNH; new WPSS score, additional baseline
More informationAML- new studies. Moderator Prof. Edo Vellenga. 1st author / speaker Mojca Jongen-Lavrencic
AML- new studies Moderator Prof. Edo Vellenga 1st author / speaker Mojca Jongen-Lavrencic Belangenverklaring In overeenstemming met de regels van de Inspectie van de Gezondheidszorg (IGZ) Naam: Organisatie:
More informationAcute Myelogenous Leukemia Pre-HSCT Data
Instructions for Acute Myelogenous Leukemia Pre-HSCT Data (Form 2010) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the AML Pre-HSCT Data Form. E-mail
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationHematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
More informationTreating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationSecondary hematologic malignancies after chemotherapy. Sasha Stanton MD PhD February 14, 2014 Dr. Tony Blau Discussant
Secondary hematologic malignancies after chemotherapy Sasha Stanton MD PhD February 14, 2014 Dr. Tony Blau Discussant Case 1 Referral from Dr. Blau (Sibel) of a 60 yo woman 3 years out of therapy for her
More informationProject Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationEvidence Review Group s Report
Evidence Review Group s Report Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Produced by Authors West Midlands Health Technology
More informationNGS e malattie mieloproliferative
NGS e malattie mieloproliferative Matteo G Della Porta Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia Medical School, Pavia, Italy matteo@haematologica.org
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationRelative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani
Relative Risk (Sokal & Hasford): Relationship with Treatment Results Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Disease risk
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationUnderstanding Myelodysplastic Syndromes: A Patient Handbook
Understanding Myelodysplastic Syndromes: A Patient Handbook Peter A. Kouides, MD John M. Bennett, MD Peter Kouides is Associate Professor of Medicine, University of Rochester School of Medicine and Dentistry,
More informationControversies in the management of patients with PMF 0/1
State of the art treatments of patients with MPNs Turracher Höhe 2010 Controversies in the management of patients with PMF 0/1 Heinz Gisslinger Medical University of Vienna Divison for Hematology, Vienna
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationAPPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
More informationBasics of AML. Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior
Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior No conflicts of interest to disclose Steven Devine, MD The Ohio State University Common
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationCI-1. DACOGEN (decitabine) United States Food and Drug Administration Oncologic Drugs Advisory Committee February 9, 2012 NDA #21790/S-010
CI-1 DACOGEN (decitabine) United States Food and Drug Administration Oncologic Drugs Advisory Committee February 9, 2012 NDA #21790/S-010 CI-2 Introduction Alton Kremer, MD, PhD Senior Vice President,
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationCLINICAL AND MOLECULAR EFFECTS OF AZACITIDINE IN THE MYELODYSPLASTIC SYNDROMES
Institutionen för medicin, Huddinge, H7 Karolinska Institutet, Stockholm, Sweden CLINICAL AND MOLECULAR EFFECTS OF AZACITIDINE IN THE MYELODYSPLASTIC SYNDROMES Magnus Tobiasson Stockholm 2015 All previously
More informationARTICLE IN PRESS Leukemia Research xxx (2010) xxx xxx
Leukemia Research xxx (2010) xxx xxx Contents lists available at ScienceDirect Leukemia Research journal homepage: www.elsevier.com/locate/leukres Clinical management of myelodysplastic syndromes: update
More informationAML: How to characterize and treat elderly patients non fit for standard chemotherapy
m1 AML: How to characterize and treat elderly patients non fit for standard chemotherapy Clinic for Medicine III University Hospital Munich Campus Grosshadern AMLCG study group Karsten Spiekermann, MD
More informationLenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality
in collaboration with: Lenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality Produced by Authors Correspondence to Kleijnen Systematic Reviews
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationFLOW CYTOMETRY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES
B. KÁRAI, E. SZÁNTHÓ, J. KAPPELMAYER, Z. HEVESSY FLOW CYTOMETRY IN THE DIAGNOSIS OF In this issue: FLOW CYTOMETRY IN THE CLINICAL LABORATORY The Journal of the International Federation of Clinical Chemistry
More informationMDS/AML and epigenetics
MDS/AML and epigenetics Moderator Prof.dr. J.H.E. Kuball 1st author / speaker Dr. G. Huls Belangenverklaring In overeenstemming met de regels van de Inspectie van de Gezondheidszorg (IGZ) Naam: Organisatie:
More information-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities
More informationCancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationThe Clinical Management of Chronic Myelomonocytic Leukemia
The Clinical Management of Chronic Myelomonocytic Leukemia Eric Padron, MD, Rami Komrokji, and Alan F. List, MD Dr Padron is an assistant member, Dr Komrokji is an associate member, and Dr List is a senior
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationTherapy-related leukemia/myelodysplastic syndrome in multiple myeloma
Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma KAZUHIKO NATORI DAISUK NAGASE SUSUMU ISHIHARA AKIKO YUKITOSHI TOYODA MOTOHIRO KATO YOSINORI FUJIMOTO YASUNOBU KURAISHI HARUKA IZUMI
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationWhat Does My Bone Marrow Do?
What Does My Bone Marrow Do? the myelodysplastic syndromes foundation, inc. Illustrations by Kirk Moldoff Published by The Myelodysplastic Syndromes Foundation, Inc. First Edition, 2009. 2012. Table of
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationSubtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
More informationUniversity of California San Diego, January 31, 2015 Part 1 Page 1 of 22
University of California San Diego, January 31, 2015 Part 1 Page 1 of 22 Sandy Kurtin, RN, MS, AOCN, ANP-C Rafael Bejar, MD, PhD Dr. Rafael Bejar: Some of the questions you have will be questions that
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationCareers in Haematology
Careers in Haematology A Guide for Medical Students and Junior Doctors Haematology is the medical speciality concerned with blood disorders. Your non-medical friends however will always think that you
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationMyeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies
Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Robert J. Arceci, M.D., Ph.D. King Fahd Professor of Pediatric Oncology Professor of Pediatrics, Oncology and
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationYumi Yamamoto, 1 Akihito Kawashima, 2,3 Eri Kashiwagi, 1,3 and Kiyoyuki Ogata 1,3. 1. Introduction
Case Reports in Hematology, Article ID 141260, 4 pages http://dx.doi.org/10.1155/2014/141260 Case Report A Jehovah s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine:
More informationin silico hematology
in silico hematology Application of mathematical modeling to predict the outcome of leukemia treatment by Ingmar Glauche and Ingo Röder Chronic Myeloid Leukemia (CML) accounts for about 20 % of all leukemias
More informationSurvival from acute non-lymphocytic leukaemia, 1971-88: a population based study
Archives of Disease in Childhood 1994; 70: 219-223 Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study 219 C A Stiller, E M Eatock Childhood Cancer Research Group, University
More informationAr Mino changes including adjustment of therapy algorithms
cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationCauses of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands
Causes of Anemia in Patients with Heart Failure Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands Background Anemia is common in patients with CHF Prevalence 15 55%
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationSynopsis of Causation. Chronic Myeloid Leukaemia
Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008
More informationOriginal Article Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus
Am J Blood Res 2013;3(2):141-164 www.ajblood.us /ISSN:2160-1992/AJBR1301001 Original Article Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus Joseph M Brandwein 1, Michelle
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationEISAI INC. FDA ODAC BRIEFING DOCUMENT NDA 021790/S-010. DACOGEN (decitabine) INDICATION: ACUTE MYELOID LEUKEMIA MEETING DATE: FEBRUARY 09, 2012
EISAI INC. FDA ODAC BRIEFING DOCUMENT NDA 021790/S-010 DACOGEN (decitabine) INDICATION: ACUTE MYELOID LEUKEMIA MEETING DATE: FEBRUARY 09, 2012 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationChronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation
Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow
More informationClinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia
Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia Clara D. Bloomfield, M.D. Distinguished University Professor The Ohio State University Comprehensive Cancer Center, and
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationWhat is acute myeloblastic leukaemia?
Acute Myeloblastic Leukaemia What is acute myeloblastic leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationGuideline for the Management of Acute Lymphoblastic Leukaemia (ALL) in Adults
Guideline for the Management of Acute Lymphoblastic Leukaemia (ALL) in Adults Version History Version Date Summary of Change/Process 1.0 The UKALL trial protocol was approved as version 1. 1.1 22.07.10
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationImmunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationNovità dall EHA >> [ Leucemia linfatica cronica ]
Novità dall EHA >> [ Leucemia linfatica cronica ] Relatore: P. GHIA 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia linfatica cronica - Copyright FSE 1 Number and type of abstracts 2 Number
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Executive Summary Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world, but is significantly less frequent in Asia. The median age of
More informationAcute Myeloid Leukemia- How can we fix it?
Acute Myeloid Leukemia- ow can we fix it? Jeffrey W. Taub, M.D. Division of ematology/ncology Children s ospital of Michigan Wayne State University School of Medicine Detroit, Michigan Proliferation of
More information